What is NAD+?
A coenzyme, not a peptide, that every human cell makes and uses in redox reactions, including mitochondrial ATP (energy) production.
US legal status
Open question
Whether the FDA will add NAD to the 503A bulks list, or keep it off, is not settled. Whether 503B outsourcing facilities may make NAD+ is open too: the FDA's 503B nominations list puts beta-NAD in Category 1, but its warning letter to GenoGenix of January 20, 2026 calls NAD+ not eligible under 503B.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
Reports to the FDA
- The FDA's adverse event database (FAERS, data to October 28, 2026) holds 48 reports with a drug named "NAD" or "NAD+", 29 marked serious, and 31 of them from 2025 or 2026; the top terms are fatigue (8), headache (6), nausea (6), anxiety (5), redness (5) and insomnia (5). Many of these reports also name vitamins and supplements and record no route, so oral products and injections cannot be told apart; the reports are not checked and do not show that NAD+ caused the event.38
What the FDA has said
In studies and reviews
- A 2026 review lists nausea, cramping, flushing and chest discomfort as effects reported across studies, and says long-term safety data are lacking (Alangari 2026).36
- Reactions during IV infusion were common in Hawkins 2024: most people given NAD+ by IV reported discomfort, including nausea, headache, diarrhea, chest tightness, lightheadedness, cramping and anxiety, which went away after the infusion ended. NAD+ infusions took about 3 hours on average, against about 2 hours for NR.14
- In Reyna 2026, all 6 of 6 people given NAD+ by IV reported moderate to severe stomach cramping, nausea, vomiting, a faster heart rate and chest pressure during the infusion, which went away when it ended. NAD+ infusions averaged 97 minutes, against 37 for NR, and took longer because of the symptoms.1537
- In Hawkins 2024, neutrophil and white blood cell counts were higher at 3 hours in the NAD+ IV group, which the authors said may reflect an inflammatory response.14
No data
Product quality
- The FDA documented an NAD+ lot with endotoxin of 3,360 EU/mL: three patients had low blood pressure, uncontrollable shaking and body aches and were sent to the emergency room. The lot, distributed nationwide, was recalled in a Class I recall.833
- The FDA's warning letter to Thrive notes that Thrive recalled all repackaged sterile products it dispensed from January 2 to April 18, 2025, for lack of sterility assurance; FDA recall records list two of them as NAD+ 100 mg/mL pre-filled syringes. The NAD+ named in the letter was 50 mg/mL.933
- FDA recall records list 16 recalls of NAD or NAD+ injections from 8 firms, started between 2017 and 2026: 1 Class I (GenoGenix, for endotoxin) and 15 Class II.33
- By reason, the 16 NAD and NAD+ injection recalls were for lack of sterility assurance (11), failed potency or reconstitution time (2), high endotoxin (1), deviations in good manufacturing practice (CGMP) monitoring (1) and beyond-use date labeling (1).33
- By the year they started, the NAD and NAD+ injection recalls number 1 in 2017, 1 in 2018, 1 in 2019, 2 in 2020, 5 in 2022, 1 in 2023, 4 in 2025 and 1 in 2026.33
- The latest recall is Apothecary Pharma's NAD+ 200 mg/mL, started September 24, 2026 for lack of sterility assurance, and still ongoing.33
Compounded NAD+ is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
- 1.FDA, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A" (updated May 14, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 2.FDA, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503B" (updated Mar 21, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 3.FDA, "Bulk Drug Substances Used in Compounding Under Section 503B"Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 4.Federal Register 91(209), Oct 30, 2026, Doc. 2026-22192 (HHS interim enforcement discretion, peptides)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 5.RAPS, "HHS will permit compounding of six peptides ahead of formal rulemaking" (Oct 29, 2026)Tier 3: reference, law firm or pressraps.orgread Nov 16, 2026↩
- 6.Federal Register, Apr 16, 2026, Doc. 2026-07361 (PCAC meeting notice)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 7.FDA, PCAC July 23–24, 2026 meeting pageTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 8.FDA Warning Letter, GenoGenix LLC, 718739 (Jan 20, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 9.FDA Warning Letter, Thrive Health and Wellness LLC, 714891 (Feb 9, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 10.HMP Global Learning Network, "FDA issues Class I recall of NAD+ injection due to elevated endotoxin levels" (citing FDA Enforcement Report Oct 22, 2025)Tier 3: reference, law firm or presshmpgloballearningnetwork.comread Nov 16, 2026
- 11.Nutritional Outlook, "FDA responds to citizen petitions on NMN..." (Sep 30, 2025)Tier 3: reference, law firm or pressnutritionaloutlook.comread Nov 16, 2026↩
- 12.Venable LLP, "FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement" (Oct 2, 2025)Tier 3: reference, law firm or pressvenable.comread Nov 16, 2026↩
- 13.Grant R. et al., "A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+", Front Aging Neurosci 2019;11:257, PMID 31572171Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 14.Hawkins et al., IV NR vs IV NAD+ randomized pilot (medRxiv preprint, 2024), doi:10.1101/2024.06.06.24308565Tier 2: peer-reviewed or trial registrymedrxiv.orgread Nov 16, 2026↩
- 15.Reyna K. et al., retrospective tolerability pilot of IV NAD+ vs NR, Frontiers in Aging 2026;7:1652582Tier 2: peer-reviewed or trial registryfrontiersin.orgread Nov 16, 2026↩
- 16.Gindri IM et al., "Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review", Am J Physiol Endocrinol Metab 2024;326(4):E417–E427, PMID 37971292 (via Europe PMC)Tier 2: peer-reviewed or trial registryebi.ac.ukread Nov 16, 2026↩
- 17.NCT06382688 (registry mirror)Tier 2: peer-reviewed or trial registryctv.veeva.comread Nov 16, 2026↩
- 18.NCT06919328 (registry mirror)Tier 2: peer-reviewed or trial registryctv.veeva.comread Nov 16, 2026↩
- 19.Niagen Bioscience, "Niagen Plus Current Evidence and Clinical Outcomes" (Aug 2026, vendor white paper)Tier 4: lead onlys205.q4cdn.comread Nov 16, 2026↩
- 20.openFDA FAERS queries (medicinalproduct "NAD+" and "nicotinamide adenine dinucleotide")Tier 1: regulator or registerapi.fda.govread Nov 16, 2026
- 21.USADA, "IV Infusions: Explanatory Note" (modified Jul 14, 2026)Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
- 22.BSCG, "NAD+: rules, risks and testing in athletics and armed forces" (Mar 16, 2026)Tier 4: lead onlybscg.orgread Nov 16, 2026↩
- 23.DEA Diversion, Controlled Substances – Alphabetical Order (Nov 12, 2026)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
- 24.USP–NF, Dietary Supplement Monograph: Nicotinamide Riboside ChlorideTier 3: reference, law firm or pressdoi.usp.orgread Nov 16, 2026↩
- 25.Empower Pharmacy, NAD+ Injection (Aqueous)Tier 4: lead onlyempowerpharmacy.comread Nov 16, 2026↩
- 26.BetterMe Rx NAD+ advertorialTier 4: lead onlybettermerx.comread Nov 16, 2026
- 27.Superpower, NAD+ Injection product pageTier 4: lead onlyclinic.superpower.comread Nov 16, 2026↩
- 28.Noom, "NAD+ injections, oral, and IV drips: What's the difference?"Tier 4: lead onlynoom.comread Nov 16, 2026
- 29.Midi Health, NAD+ Nasal Spray product monographTier 4: lead onlyjoinmidi.comread Nov 16, 2026
- 30.Eden press release (via B2B Local)Tier 4: lead onlynews.b2blocal.comread Nov 16, 2026↩
- 31.Partnership for Safe Medicines statement (Jul 22, 2026)Tier 4: lead onlysafemedicines.orgread Nov 16, 2026
- 32.News12 Bronx, "Prosecutors: unauthorized NAD+ IV infusion led to woman's death" (Jul 21, 2026)Tier 3: reference, law firm or pressbronx.news12.comread Nov 16, 2026↩
- 33.openFDA, drug enforcement (recall) reports, `product_description:"NAD"` and `"nicotinamide adenine"` (data to Nov 4, 2026)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 34.Grant R et al., Front Aging Neurosci 2019;11:257, full text PMC6751327 (Methods: participants)Tier 2: peer-reviewed or trial registrypmc.ncbi.nlm.nih.govread Nov 16, 2026↩
- 35.ClinicalTrials.gov API v2: intervention search "NAD+" OR "nicotinamide adenine dinucleotide" (271 studies) and records NCT06382688, NCT06919328, NCT07475546Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026↩
- 36.Alangari A et al., "Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine", Front Aging 2026;7:1887175, PMID 42787547Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 37.Reyna K et al., Front Aging 2026;7:1652582, PubMed abstract PMID 41704678Tier 2: peer-reviewed or trial registrypubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 38.openFDA FAERS, `patient.drug.medicinalproduct:"NAD"`: reactions, seriousness, received date (data to Oct 28, 2026)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 39.PubMed E-utilities counts: "nicotinamide mononucleotide"[tiab], "nicotinamide riboside"[tiab], each with randomized controlled trial[pt]Tier 1: regulator or registereutils.ncbi.nlm.nih.govread Nov 16, 2026
- 40.FDA, "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act"Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 41.FDA Warning Letter, ProRx LLC, MARCS-CMS 723704 (Apr 7, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 42.FDA Close-out Letter, Thrive Health and Wellness LLC dba Thrive Health Solutions, MARCS-CMS 714891 (Jul 27, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 43.Federal Register API, documents search `conditions[term]=nicotinamide adenine` and `nicotinamide mononucleotide` (since 2025-01-01; 0 results) and `compounding peptides` (since 2026-10-30)Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
- 44.FDA Warning Letters database, full-text search "nicotinamide adenine dinucleotide" and "NAD+" (content current as of Nov 13, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
We review programs, not the drugs they sell. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.